COMP <GO>
AORT vs JNJ // RSI-14 & 200D SMA MOMENTUM
Artivion Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: AORT 2
— JNJ 10
▲ RSI-14 & 200D SMA MOMENTUM LEADER: JNJ
LAST: $23.44 (+2.27%) • MKT CAP: $1.14B
rsi-technicals
46.6
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
rsi-technicals
62.1
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AORT VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AORT | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.40% | 67.90% | -3.50 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.50% | 25.50% | -21.00 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.3x | 18.5x | +0.80 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 0.07% | 2.97% | -2.90 | JNJ | /fcf-yield <GO> |
| Operating Margin | 7.60% | 34.70% | -27.10 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 2.20% | 28.50% | -26.30 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 13.60% | 6.00% | +7.60 | AORT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.46 | 5.59 | -3.13 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | AORT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 46.6 | 62.1 | -15.52 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 98.3x | 23.0x | +75.30 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.14B | $662.49B | -$661.35B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AORT REV | JNJ REV | AORT GROSS % | JNJ GROSS % | AORT FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $441.3M | $94.19B | 64.4% | 67.9% | $839.0K | $19.70B |
| FY 2024 | $388.5M | $88.82B | 64.0% | 69.1% | $11.0M | $19.84B |
| FY 2023 | $354.0M | $85.16B | — | — | $18.8M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AORT // BETA —
JNJ // BETA 1.08